Royalty Pharma plcRPRXNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank48
Year-over-Year Change
Year-over-year operating income growth rate
Percentile
P48
Within normal range
vs 2Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -9.08% |
| Q3 2025 | 103.60% |
| Q2 2025 | -60.73% |
| Q1 2025 | 47.76% |
| Q4 2024 | -50.82% |
| Q3 2024 | 172.62% |
| Q2 2024 | 465.48% |
| Q1 2024 | -112.04% |
| Q4 2023 | 304.71% |
| Q3 2023 | -39.14% |
| Q2 2023 | -48.05% |
| Q1 2023 | 199.24% |
| Q4 2022 | -351.11% |
| Q3 2022 | -49.12% |
| Q2 2022 | 71.94% |
| Q1 2022 | 43.22% |
| Q4 2021 | -49.38% |
| Q3 2021 | -59.32% |
| Q2 2021 | 224.88% |
| Q1 2021 | -26.99% |
| Q4 2020 | -38.49% |
| Q3 2020 | 24.73% |
| Q2 2020 | 13.26% |
| Q1 2020 | -72.86% |
| Q4 2019 | 150.13% |
| Q3 2019 | 62.42% |
| Q2 2019 | -23.91% |
| Q1 2019 | 0.00% |